Quality Sustainability in Pharma: Where Culture Becomes the True Competitive Edge

AstraZeneca takes a 12% stake in Summit Therapeutics for $2 billion to co-develop ivonescimab, a PD-1/VEGF bispecific antibody.

Indirect analysis of ACHIEVE-3 and PIONEER PLUS data positions Lilly's Foundayo ahead of oral semaglutide on weight loss, with manufacturing scalability implications for both molecules.

Novo Nordisk licenses Hengrui's oral GLP-1 candidate for up to $2.6B, signalling a manufacturing pivot toward solid-dose in the weight-loss drug space.

FDA and CRCG host a two-day LAI generics workshop in December 2026, targeting IVRT, bioequivalence, and ANDA deficiency patterns for complex injectables.